In vitro Characterization of Anti-SARS-CoV-2 Intravenous Immunoglobulins (IVIg) Produced From Plasma of Donors Immunized With the BNT162b2 Vaccine and Its Comparison With a Similar Formulation Produced From Plasma of COVID-19 Convalescent Donors

• Published in: Frontiers in medical technology Vol. 3; p. 772275
• Main Authors: Rojas-Jiménez, Gabriel, Solano, Daniela, Segura, Álvaro, Sánchez, Andrés, Chaves-Araya, Stephanie, Herrera, María, Vargas, Mariángela, Cerdas, Maykel, Calvo, Gerardo, Alfaro, Jonathan, Molina, Sebastián, Bolaños, Kimberly, Moreira-Soto, Andrés, Villalta, Mauren, Sánchez, Adriana, Cordero, Daniel, Durán, Gina, Solano, Gabriela, Gómez, Aarón, Hernández, Andrés, Sánchez, Laura, Vargas, Marco, Drexler, Jean Felix, Alape-Girón, Alberto, Díaz, Cecilia, León, Guillermo
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 05.01.2022
• Subjects: BNT162b2 vaccine; convalescent plasma; COVID-19; hyperimmune plasma; hyperimmune polyclonal antibodies; IVIg; Medical Technology; COVID-19; BNT162b2 vaccine; SARS-CoV-2; hyperimmune polyclonal antibodies; IVIg; hyperimmune plasma; passive immunotherapy; convalescent plasma

Despite vaccines are the main strategy to control the ongoing global COVID-19 pandemic, their effectiveness could not be enough for individuals with immunosuppression. In these cases, as well as in patients with moderate/severe COVID-19, passive immunization with anti-SARS-CoV-2 immunoglobulins coul...